Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis

Kaohsiung Medical University Chung-Ho Memorial Hospital60 enrolled

Overview

To determine the cumulative incidence of total hip replacement, time to event after treatment with Fosamax or placebo during the study peroid

To determine the cumulative incidence of total hip replacement and collpase of femoral head, time to event after treatment with Fosamax or placebo during the study peroid

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Non-Traumatic Osteonecrosis

Interventions

AlendronateDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * osteonecrosis of femoral head * be able to provide singed informed consent Exclusion Criteria: * prior bisphosphonate use * pregnant or lactating woman * bilateral hip replacement

Locations (1)

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, Taiwan

Outcomes

Primary Outcomes

the cumulative of total hip replacement

Secondary Outcomes

necrotic area

Harris hip score

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.